Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further ...

Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further devel ...

The support from the FDA for the continued development of nadunolimab in the high IL1RAP subset of PDAC patients further strengthens our efforts to bring this potentially important new treatment ...

Nadunolimab is a fully humanized Fc-enhanced IgG1 monoclonal antibody targeting interleukin 1 receptor accessory protein.

Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels. Reflects high unmet medical need in metastatic PDAC. Facilitates further ...

Nadunolimab is a fully humanized Fc-enhanced IgG1 monoclonal antibody targeting IL1RAP. The fast track designation is supported by data from the phase 2 CANFOUR trial (NCT03267316). Cantargia ...